论文部分内容阅读
目的观察应用低分子肝素钙治疗不稳定心绞痛(UA)的临床疗效及安全性。方法选择2004年2月至2005年10月在我院住院的UA患者54例,随机分为治疗组、对照组。常规治疗基础上治疗组选用赛诺菲(中国)公司生产的低分子肝素钙(速避凝)0.4 ml,2次/d,腹壁皮下注射,连用7 d。结果治疗组患者治疗后与对照组比较,心绞痛发作次数明显减少,心肌缺血明显改善,两组比较差异有显著性。结论低分子肝素钙治疗UA安全,有效。
Objective To observe the clinical efficacy and safety of low molecular weight heparin in the treatment of unstable angina pectoris (UA). Methods 54 patients with UA who were hospitalized in our hospital from February 2004 to October 2005 were randomly divided into treatment group and control group. On the basis of routine treatment, 0.4 ml of low molecular weight heparin (fast evacuation) produced by Sanofi (China) Co., Ltd. was used twice a day for 7 days in the treatment group. Results Compared with the control group, the number of angina pectoris and the myocardial ischemia in the treatment group were significantly decreased after treatment. The difference between the two groups was significant. Conclusion Low molecular weight heparin is safe and effective in the treatment of UA.